Furthermore, SMARCA4 deficiency is easily determined by immunohistochemistry (IHC), which demonstrates the loss of nuclear expression of SMARCA4 protein in the tumor cell nuclei.[6] SMARCA4-UT demonstrates a relevant metastatic tendency and a lower response to platinum-based chemotherapy,[7–9] and the mean patient survival time is only 4 to 7 months after definite diagnosis.[5] Here, we discuss a male patient with SMARCA4-UT who maintained a high quality of life after surgery that far exceeded his predicted survival. Here, SMARCA4 is linked to neoplasm.